Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics Files $100M Shelf Registration

NEW YORK (GenomeWeb News) – Complete Genomics has filed to raise up to $100 million in a public offering.

In a Form S-3 filed with the US Securities and Exchange Commission on Friday, the company said that it may seek to raise the funds through the sale of preferred stock, debt securities, and warrants from time to time. Use of proceeds will go toward general corporate purposes, including R&D, increase of working capital, reduction of indebtedness, acquisitions, investments into the business, and capital expenditures.

Complete Genomics had raised around $74 million through a public offering of 6.3 million shares of its common stock at $12.50 per share in early June.

The Mountain View, Calif.-based firm reported in November flat third-quarter revenues, and earlier this month, some analysts lowered their estimates for the company after CFO Ajay Bansal said that Complete Genomics expects to ship about 900 genomes during the fourth quarter, the low end of guidance it had provided earlier.

In afternoon trading on Nasdaq shares of Complete Genomics were down around 4 percent at $2.73.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.